Urinary Incontinence - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Urinary Incontinence - Pipeline Review, H2 2018’, provides an overview of the Urinary Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence

- The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects

- The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Urinary Incontinence

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Beech Tree Labs Inc

Crystec Ltd

Fate Therapeutics Inc

FemmePharma Global Healthcare Inc

GTx Inc

Innovacell Biotechnologie AG

Ipsen SA

Mylan NV

Pfizer ...

Allergan Plc

Beech Tree Labs Inc

Crystec Ltd

Fate Therapeutics Inc

FemmePharma Global Healthcare Inc

GTx Inc

Innovacell Biotechnologie AG

Ipsen SA

Mylan NV

Pfizer Inc

Saniona AB

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Taris Biomedical LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Urinary Incontinence - Overview

Urinary Incontinence - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Urinary Incontinence - Overview

Urinary Incontinence - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Urinary Incontinence - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Urinary Incontinence - Companies Involved in Therapeutics Development

Allergan Plc

Beech Tree Labs Inc

Crystec Ltd

Fate Therapeutics Inc

FemmePharma Global Healthcare Inc

GTx Inc

Innovacell Biotechnologie AG

Ipsen SA

Mylan NV

Pfizer Inc

Saniona AB

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Taris Biomedical LLC

Urinary Incontinence - Drug Profiles

abobotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-hs - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Gastrointestinal Disorders, Ischemic Heart Failure and Urological Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enobosarm - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gtx-027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICES-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

litoxetine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prof-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolterodine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trospium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Urinary Incontinence - Dormant Projects

Urinary Incontinence - Discontinued Products

Urinary Incontinence - Product Development Milestones

Featured News & Press Releases

May 18, 2018: GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting

Apr 16, 2018: GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting

Apr 09, 2018: GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Mar 05, 2018: GTx Announced New Data Demonstrating Enobosarm's Potential to Treat Stress Urinary Incontinence at SUFU 2018

Feb 22, 2018: GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU

Jan 11, 2018: Sleep quality improves with help of incontinence drug

Sep 21, 2017: GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City

Sep 13, 2017: GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

Jun 12, 2017: GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

May 11, 2017: GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting

Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Urinary Incontinence, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Urinary Incontinence, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Urinary Incontinence - Pipeline by Allergan Plc, H2 2018

Urinary Incontinence - Pipeline by Beech Tree Labs Inc, H2 2018

Urinary Incontinence - Pipeline by Crystec Ltd, H2 2018

Urinary Incontinence - Pipeline by Fate Therapeutics Inc, H2 2018

Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H2 2018

Urinary Incontinence - Pipeline by GTx Inc, H2 2018

Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2018

Urinary Incontinence - Pipeline by Ipsen SA, H2 2018

Urinary Incontinence - Pipeline by Mylan NV, H2 2018

Urinary Incontinence - Pipeline by Pfizer Inc, H2 2018

Urinary Incontinence - Pipeline by Saniona AB, H2 2018

Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Urinary Incontinence - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Urinary Incontinence - Pipeline by Taris Biomedical LLC, H2 2018

Urinary Incontinence - Dormant Projects, H2 2018

Urinary Incontinence - Dormant Projects, H2 2018 (Contd..1), H2 2018

Urinary Incontinence - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Urinary Incontinence, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Urinary Incontinence, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports